Released Apr 30, 2026, before the open
10-Q filed Apr 30, 2026, 30 days after period end · 0000059478-26-000045
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2026 and provided updated 2026 financial guidance.
The release| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $19.80B | $12.73B | $8.77B | $6.96B |
| Net Income | $7.40B | $2.76B | $2.24B |
Eli Lilly & Co · CIK 59478 · Engraved from SEC EDGAR
| $1.34B |
| EPS Diluted | $8.26 | $3.06 | $2.48 | $1.49 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lilly reported Q1 2026 revenue of $19.8 billion, up 56%, and reported EPS of $8.26, up 170%.¶2¶3
Non-GAAP Q1 2026 EPS increased 156% to $8.55, while reported and non-GAAP EPS included $0.52 of acquired IPR&D charges compared to $1.72 in Q1 2025.¶3
Lilly raised 2026 full-year revenue guidance to $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00.¶4
The U.S. FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.¶5